Syantra

Syantra is a biotech company that uses its flagship blood test, Syantra DXTM Breast Cancer, for the early detection of breast cancer to help optimize treatment. The company also uses its discovery platform, which includes the FlowPlate device, biobank, and clinical and molecular profile database, to identify novel biomarkers and drug targets to support candidate selection for clinical trials.

The Syantra DXTM Breast Cancer test is a minimally invasive blood test that evaluates 12 gene expression biomarkers using proprietary software and machine-learning-derived algorithms to interpret the data. It detects active breast cancer in its earliest stages, making treatment easier. Syantra claims that its test may improve detection, especially for high-risk individuals, such as those with genetic predisposition, dense breasts, or diverse ethnic backgrounds, for whom mammograms may be inadequate. The test obtained CE marking in April 2023, enabling the company to market the blood test in the EU and other countries that recognize the marking.

Key Customers and Partnerships

The company has several key partners including TapLabs (2021) to offer the breast cancer screening test to TapLabs patients at their homes, Calian (October 2022) to offer the breast cancer screening test in 100+ cities in Canada, and Avvy Health (April 2022) to offer the breast cancer screening test in Montreal. 

Funding and Financials

In January 2022, the company raised USD 6.8 million in a Series A funding round led by a consortium group of doctors in Canada through Rejuvenation Health. The funds raised were used toward commercialization of the DX platform, expanding its lab facility in Calgary, and for clinical study.